Quick Answer
Oncology Institute, Inc. reported Operating Income Loss of -$36.08 million for the year ending 2025.
- Oncology Institute, Inc. showed an increase of +40.0% in Operating Income Loss from 2024 to 2025.
- This data is from Oncology Institute, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2019: -$2.3 thousand | Q1 2020: -$87.8 thousand | Q2 2020: -$194.6 thousand | Q3 2020: -$198.5 thousand | Q1 2021: -$1.75 million | Q2 2021: -$1.12 million | Q3 2021: -$2.16 million | Q1 2022: -$18.47 million | Q2 2022: -$18.30 million | Q3 2022: -$20.10 million | Q1 2023: -$32.87 million | Q2 2023: -$14.94 million | Q3 2023: -$13.93 million | Q1 2024: -$17.97 million | Q2 2024: -$16.36 million | Q3 2024: -$13.85 million | Q1 2025: -$9.91 million | Q2 2025: -$11.21 million | Q3 2025: -$8.05 million.
- Over the full 6 years of available data (2020 to 2025), Oncology Institute, Inc.'s Operating Income Loss has declined by 340.2%.
- Historical annual values: Fiscal year 2025: -$36.08 million | Fiscal year 2024: -$60.12 million | Fiscal year 2023: -$77.02 million | Fiscal year 2022: -$81.95 million | Fiscal year 2021: -$45.86 million | Fiscal year 2020: -$8.20 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: